BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 22414636)

  • 1. In vivo evaluation of a cancer therapy strategy combining HSV1716-mediated oncolysis with gene transfer and targeted radiotherapy.
    Sorensen A; Mairs RJ; Braidwood L; Joyce C; Conner J; Pimlott S; Brown M; Boyd M
    J Nucl Med; 2012 Apr; 53(4):647-54. PubMed ID: 22414636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment in vitro of a novel therapeutic strategy for glioma, combining herpes simplex virus HSV1716-mediated oncolysis with gene transfer and targeted radiotherapy.
    Quigg M; Mairs RJ; Brown SM; Harland J; Dunn P; Rampling R; Livingstone A; Wilson L; Boyd M
    Med Chem; 2005 Sep; 1(5):423-9. PubMed ID: 16787326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A transfectant mosaic xenograft model for evaluation of targeted radiotherapy in combination with gene therapy in vivo.
    Mairs RJ; Ross SC; McCluskey AG; Boyd M
    J Nucl Med; 2007 Sep; 48(9):1519-26. PubMed ID: 17704246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression in UVW glioma cells of the noradrenaline transporter gene, driven by the telomerase RNA promoter, induces active uptake of [131I]MIBG and clonogenic cell kill.
    Boyd M; Mairs RJ; Mairs SC; Wilson L; Livingstone A; Cunningham SH; Brown MM; Quigg M; Keith WN
    Oncogene; 2001 Nov; 20(53):7804-8. PubMed ID: 11753659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A gene therapy/targeted radiotherapy strategy for radiation cell kill by.
    Boyd M; Mairs RJ; Cunningham SH; Mairs SC; McCluskey A; Livingstone A; Stevenson K; Brown MM; Wilson L; Carlin S; Wheldon TE
    J Gene Med; 2001; 3(2):165-72. PubMed ID: 11318115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
    Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
    Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of inhibitor of growth 4 by HSV1716 improves oncolytic potency and enhances efficacy.
    Conner J; Braidwood L
    Cancer Gene Ther; 2012 Jul; 19(7):499-507. PubMed ID: 22595793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiation-mediated bystander effects.
    Boyd M; Mairs RJ; Keith WN; Ross SC; Welsh P; Akabani G; Owens J; Vaidyanathan G; Carruthers R; Dorrens J; Zalutsky MR
    J Gene Med; 2004 Aug; 6(8):937-47. PubMed ID: 15293352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Noradrenaline transporter gene transfer for radiation cell kill by 131I meta-iodobenzylguanidine.
    Boyd M; Cunningham SH; Brown MM; Mairs RJ; Wheldon TE
    Gene Ther; 1999 Jun; 6(6):1147-52. PubMed ID: 10455418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of targeted radiotherapy/gene therapy to bladder cancer cell lines.
    Fullerton NE; Mairs RJ; Kirk D; Keith WN; Carruthers R; McCluskey AG; Brown M; Wilson L; Boyd M
    Eur Urol; 2005 Feb; 47(2):250-6. PubMed ID: 15661422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A strategy for systemic delivery of the oncolytic herpes virus HSV1716: redirected tropism by antibody-binding sites incorporated on the virion surface as a glycoprotein D fusion protein.
    Conner J; Braidwood L; Brown SM
    Gene Ther; 2008 Dec; 15(24):1579-92. PubMed ID: 18701918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [131I]meta-iodobenzylguanidine and topotecan combination treatment of tumors expressing the noradrenaline transporter.
    McCluskey AG; Boyd M; Ross SC; Cosimo E; Clark AM; Angerson WJ; Gaze MN; Mairs RJ
    Clin Cancer Res; 2005 Nov; 11(21):7929-37. PubMed ID: 16278418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transfectant mosaic spheroids: a new model for evaluation of tumour cell killing in targeted radiotherapy and experimental gene therapy.
    Boyd M; Mairs SC; Stevenson K; Livingstone A; Clark AM; Ross SC; Mairs RJ
    J Gene Med; 2002; 4(5):567-76. PubMed ID: 12221650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiation quality-dependent bystander effects elicited by targeted radionuclides.
    Boyd M; Sorensen A; McCluskey AG; Mairs RJ
    J Pharm Pharmacol; 2008 Aug; 60(8):951-8. PubMed ID: 18644188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of poly(ADP-Ribose) polymerase enhances the toxicity of 131I-metaiodobenzylguanidine/topotecan combination therapy to cells and xenografts that express the noradrenaline transporter.
    McCluskey AG; Mairs RJ; Tesson M; Pimlott SL; Babich JW; Gaze MN; Champion S; Boyd M
    J Nucl Med; 2012 Jul; 53(7):1146-54. PubMed ID: 22689924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
    Jacobs A; Tjuvajev JG; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson SM; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO; Blasberg RG
    Cancer Res; 2001 Apr; 61(7):2983-95. PubMed ID: 11306477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxic effects of the oncolytic herpes simplex virus HSV1716 alone and in combination with cisplatin in head and neck squamous cell carcinoma.
    Mace AT; Harrow SJ; Ganly I; Brown SM
    Acta Otolaryngol; 2007 Aug; 127(8):880-7. PubMed ID: 17763002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining a targeted radiotherapy and gene therapy approach for adenocarcinoma of prostate.
    Fullerton NE; Boyd M; Mairs RJ; Keith WN; Alderwish O; Brown MM; Livingstone A; Kirk D
    Prostate Cancer Prostatic Dis; 2004; 7(4):355-63. PubMed ID: 15477875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival.
    Harrow S; Papanastassiou V; Harland J; Mabbs R; Petty R; Fraser M; Hadley D; Patterson J; Brown SM; Rampling R
    Gene Ther; 2004 Nov; 11(22):1648-58. PubMed ID: 15334111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy.
    Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Martuza RL; Rabkin SD; Kurtz A
    Mol Ther; 2006 Dec; 14(6):789-97. PubMed ID: 17045531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.